LEHI, Utah, 5 juin, 2025 /PRNewswire/ -- Halia Therapeutics, une société biopharmaceutique au stade clinique, pionnière dans les thérapies inspirées par la résilience génétique, a annoncé aujourd'hui la fin du recrutement pour son essai clinique ouvert de phase 2a évaluant le HT-6184...
Hence then, the article about halia therapeutics acheve le recrutement pour l essai clinique de phase 2a du ht 6184 pour le syndrome myelodysplasique smd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Halia Therapeutics achève le recrutement pour l'essai clinique de phase 2a du HT-6184 pour le syndrome myélodysplasique (SMD) )
Also on site :
- UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
- AI boom fuels fears of an industry bubble (VIDEO)
- Amazon Has 'Super Warm' and ‘Soft' Mini Sheepskin Boots on Sale for $50, and They're 'Worth Every Penny'